Cellular Immunotherapies for Multiple Sclerosis: Mechanistic Insights and Clinical Advances

TL;DR

This paper reviews cellular immunotherapy approaches for multiple sclerosis, focusing on how immune cells contribute to the disease and new treatment strategies.

Contribution

The paper provides a comprehensive review of novel cellular immunotherapy methods for multiple sclerosis.

Findings

Multiple sclerosis involves immune cell infiltration causing CNS damage.

Cellular immunotherapies aim to modulate immune responses in MS patients.

Early diagnosis and targeted treatments are improving MS management.

Abstract

Multiple sclerosis (MS) is a chronic, heterogeneous, multifactorial, immune-mediated neurodegenerative disease of the central nervous system that affects the working-age population. Its development is influenced by both genetic and environmental factors. A pathological hallmark of MS is the formation of demyelinating lesions in the brain and spinal cord, which are associated with neuronal damage caused by autoaggressive immune factors (T cells, B cells, and myeloid cells). Focal lesions are believed to be caused by the infiltration of immune cells into the central nervous system (CNS) parenchyma with concomitant tissue damage. Multiple sclerosis represents a significant social problem due to the high cost of available treatments, as well as the deterioration of employment prospects and job retention for both patients and their caregivers. Advances in MS diagnostic methods have enabled disease detection at early stages and correction of immune response impairments. Concurrently, treatments for MS patients are actively being studied, with the ongoing development of novel methods for targeted and cellular immunotherapy. This review primarily discusses approaches to cellular immunotherapy and methods of influencing the cellular arm of immunopathogenesis in multiple sclerosis.

Figures